Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | General Counsel, Secretary | February 22, 2024 | February 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date February 22, 2024 · Filed February 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,125 |
Reported balance
After 2024-02-22 transaction · row 1
1 source rowRow 1 · 2024-02-22 · Grant · Acquired 28,125 · Balance 28,125 F1: Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date. F2: Each RSU represents a contingent right to receive one share of Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2034-02-21 | Direct | 168,750 |
Reported balance
After 2024-02-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-22 · Grant · Acquired 168,750 · Balance 168,750 F3: 25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date.
F2: Each RSU represents a contingent right to receive one share of Common Stock.
F3: 25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2024 Filed Feb 26, 2024 23:00 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001209191-24-003966 · doc4.xml · derivative · entry 2 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2034-02-21 F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 23:00 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantCommon Stock | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003966 · doc4.xml · nonDerivative · entry 1 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,125 F1 · shares: Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:00 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-23-013239 · doc4.xml · derivative · entry 1 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-02-22 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2024 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-22-024185 · doc4.xml · derivative · entry 2 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-07 F2 · derivative.exercise_date: The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on April 8, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous services through such vesting date. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 25,399 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-22-024185 · doc4.xml · derivative · entry 1 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,399 Underlying: Common Stock · 25,399 shares Expires 2032-04-07 F1 · derivative.exercise_date: The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 23:19 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-22-007310 · doc4.xml · derivative · entry 1 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 3, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 22:04 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001209191-20-064674 · doc4.xml · derivative · entry 1 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on December 17, 2021 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| November 25, 2020 Filed Apr 29, 2021 21:32 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001209191-21-029048 · doc4.xml · derivative · entry 1 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2030-05-04 F1 · derivative.exercise_date: On May 5, 2020, the Reporting Person was granted the option to purchase shares of the Issuer's common stock, subject to a performance-based vesting condition to be satisfied upon the achievement of a particular milestone related to the Issuer's clinical trial, and further subject to the Reporting Person's continuous service through such vesting date. Such option vested in full on November 25, 2020 upon the satisfaction of such performance-based vesting condition. Read SEC document |
| October 11, 2020 Filed Oct 13, 2020 20:38 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001209191-20-054642 · doc4.xml · derivative · entry 1 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-10-10 F1 · derivative.exercise_date: 50% of the shares subject to the Stock Option will vest and become exercisable on October 11, 2021 and the remaining shares will vest in 12 equal installments thereafter, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 00:47 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001209191-20-000452 · doc4.xml · derivative · entry 1 Perone Thomas Michael · CIK 0001771761 · General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 1, 2021 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:18 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001209191-19-061538 · doc4.xml · derivative · entry 1 Perone Thomas Michael · CIK 0001771761 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-12-17 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on December 18, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| April 03, 2019 Filed Apr 9, 2019 00:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001209191-19-024055 · doc4.xml · derivative · entry 1 Perone Thomas Michael · CIK 0001771761 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-03-24 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.